The Committee discusses GlaxoSmithKline’s investigational new drug application (IND) 157775, for Dostarlimab-gxly for injection. The proposed indication (use) for this product is as a single agent for treatment of patients with locally advanced, treatment-naive mismatch repair deficiency/microsatellite instability-high rectal cancer in a meeting to be held on February 9 at 11 am. Webcast Link
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on GSK:
- FDA Oncologic Drugs Advisory Committee to hold a virtual meeting
- GSK, Cytel enter three-year agreement to expand Solara deployment
- GSK price target raised to 1,400 GBp from 1,350 GBp at JPMorgan
- Akebia should update on vadadustat FDA process in next month, says Piper Sandler
- GSK reports Jesduvroq approved by FDA for anemia of CKD in adults on dialysis
